Regulatory Mandate for Post‑Marketing Surveillance Raises Questions on Statutory Authority, Procedural Fairness, and Judicial Review in India’s Pharmaceutical Sector

India’s drug regulator has issued a directive requiring all pharmaceutical manufacturers to create and maintain comprehensive mechanisms for the systematic collection, documentation, and reporting of adverse drug reactions that occur after a product has entered the market, thereby extending the responsibilities traditionally associated with pre‑marketing approval. The order, explicitly anchored in Schedule M of the Drugs and Cosmetics Rules, mandates that each company develop robust post‑marketing surveillance systems capable of detecting, analysing, and communicating rare or delayed side effects to the regulator in a timely manner, thus reinforcing the statutory framework that obliges manufacturers to safeguard public health beyond initial product launch. By aligning the national requirement with a broader international movement toward real‑world evidence collection, the regulator seeks to ensure that pharmacovigilance practices within India are consistent with global standards, thereby facilitating the early identification of safety signals that might otherwise remain unnoticed until they manifest in larger patient populations. The directive therefore creates a legal obligation for pharmaceutical firms to integrate adverse event monitoring into their operational processes, to allocate appropriate resources for data management, and to establish clear lines of communication with regulatory authorities, all of which may have implications for compliance audits, potential penalties, and the scope of judicial review in cases of alleged negligence. Furthermore, the emphasis on robust post‑marketing surveillance reflects an expectation that companies will not only respond to individual reports but also proactively analyse aggregate data to identify patterns, thereby fulfilling a statutory duty that may be subject to enforcement action should the regulator determine that the monitoring systems are inadequate or ineffective.

One question is whether the drug regulator possesses clear statutory authority under Schedule M of the Drugs and Cosmetics Rules to impose detailed post‑marketing surveillance obligations that extend beyond mere notification requirements, thereby creating a binding duty enforceable through administrative penalties. The answer may depend on the interpretive approach applied to Schedule M, which historically outlines the responsibilities of manufacturers regarding manufacturing processes and product testing, raising the possibility that a broader reading could be justified to meet contemporary pharmacovigilance expectations. Perhaps the more important legal issue is whether non‑compliance with the mandated surveillance systems can attract penal consequences such as suspension of manufacturing licences, monetary fines, or directives to recall products, and if so, what procedural safeguards are required before such sanctions are imposed.

Perhaps the procedural significance lies in the requirement that the regulator provide affected firms with an opportunity to be heard, thereby satisfying the principle of natural justice that mandates a fair hearing before the imposition of any adverse administrative action. One may also ask whether the regulator must disclose the specific evidentiary basis for concluding that a company's post‑marketing system is inadequate, as such disclosure could be essential for the affected party to meaningfully contest the allegation during any subsequent appeal or judicial review proceeding. Perhaps a competing view may argue that the regulator, acting under a broad public‑health mandate, could rely on a presumption of non‑compliance in the absence of satisfactory evidence, thereby limiting the scope of the hearing to a formality rather than a substantive opportunity to defend the surveillance framework.

Another possible view is that any penalty imposed for failure to establish robust adverse‑event monitoring must satisfy the constitutional test of proportionality, meaning that the punitive measure should not be excessive in relation to the public‑health objective pursued by the regulator. The answer may turn on whether the regulator’s enforcement powers under the Rules include the authority to levy monetary fines without prior adjudication, which raises the question of whether such a procedure respects the due‑process guarantees embedded in the constitutional framework. Perhaps the more important legal question is whether a company aggrieved by an adverse regulatory order can seek relief through an appeal before a designated tribunal or through a writ petition in a high court, thereby invoking the jurisdictional competence of the judiciary to review administrative action for legality and reasonableness.

In sum, the regulator’s directive compels pharmaceutical firms to integrate comprehensive adverse‑event surveillance into their operational regimes, and the attendant legal questions concerning statutory authority, procedural fairness, proportionality of sanctions, and avenues for judicial review will shape how the industry aligns its compliance strategies with evolving public‑health imperatives. Future clarification from the regulator or judicial pronouncements could further delineate the precise compliance timeline and the extent of evidence required to satisfy the statutory monitoring obligations.